Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low-risk differentiated thyroid cancer (DTC), which comprises the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up [1,2]. The gene discussed is TG; the disease is differentiated thyroid carcinoma.